Search
Search Results
-
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
BackgroundAn international retrospective cohort study was conducted to clarify the survival advantage of combination therapy with locoregional and...
-
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
IntroductionNeoadjuvant systemic therapy (NAST) is vital in the management of HER2-positive (HER2+) breast cancer. Nevertheless, the indications for...
-
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study
PurposeNeoadjuvant systemic therapy (NST) is increasingly used in breast cancer patients and depending on subtype, 10–89% of patients will attain...
-
The Attachment Map** Protocol (AMP): An Assessment and Treatment Tool for General Psychotherapy, Systemic Family Therapy and Multifaith Spiritual Care
This paper introduces the Attachment Map** Protocol (AMP), which is an assessment and treatment tool for use in individual psychotherapy, systemic...
-
Upfront primary tumor resection versus upfront systemic therapy for metastatic colorectal cancer: a systematic review and meta-analysis
PurposeThe standard initial treatment for metastatic colorectal cancer (mCRC) remains debated. This study investigated whether upfront primary tumor...
-
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
PurposeDuring the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite...
-
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
BackgroundFirst-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line...
-
A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China
BackgroundChronic graft-versus-host disease (cGVHD) is an immune-related disorder that is the most common complication post-allogenic hematopoietic...
-
MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy
Systemic lupus erythematosus (SLE) is an autoimmune disease associated with hyperactive innate and adaptive immune systems that cause dermatological,...
-
Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement
Heyde syndrome is characterized by the co-occurrence of aortic stenosis and bleeding gastrointestinal angiodysplasias, often with acquired von...
-
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
BackgroundLenvatinib combined with pembrolizumab showed a promising result in an early phase study for hepatocellular carcinoma (HCC). The efficacy...
-
Systemic bevacizumab for treatment of recurrent respiratory papillomatosis
ObjectivesTo characterize treatment response of recurrent respiratory papillomatosis (RRP) including adult-onset RRP (AORRP) and juvenile-onset RRP...
-
Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review
Purpose of ReviewIntravitreal anti-vascular endothelial growth factor (VEGF) agents are used routinely in the management of neovascular conditions...
-
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
PurposeCirculating miRNAs can provide valid prognostic and predictive information for breast cancer diagnosis and subsequent management. They may...
-
Antibiotics vs observational therapy in acute uncomplicated diverticulitis, a systemic review and meta-analysis
PurposeAntibiotics have long been recommended as a form of conservative therapy in patients with acute uncomplicated diverticulitis despite no...
-
Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
IntroductionSystemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma...
-
Systemic Therapy for Chondrosarcoma
Clinical trial enrollment should be actively encouraged in all patients diagnosed with advanced, surgically unresectable chondrosarcoma (CS) due to...
-
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared...
-
Benefits of Trimodality Therapy Compared with Systemic Therapy Alone in Male Patients with Stage IV Breast Cancer
BackgroundMale breast cancer (MBC) represents <1% of all breast cancer (BC) diagnoses. Recent publications in female stage IV BC have shown that...
